KAHR is a clinical-stage oncology company developing novel, dual-targeting fusion proteins that are engineered to activate both the innate and the adaptive immune systems and localize that response in the tumor microenvironment. KAHR's products are designed to be highly specific, capable of both unblocking key immunosuppressive mechanisms and simultaneously activating downstream signals that stimulate key immune cells. KAHR's lead product candidate, DSP107, selectively targets CD47 and 4-1BB to overcome the safety limitations of first generation products aimed at these targets. DSP107 has shown deep and durable responses in both 2L/3L NSCLC and 3L MSS CRC when combined with atezolizumab, and complete responses in 2L MDS when combined with azacitidine. We are also developing DSP502 (PVR x PD-L1 targeting fusion protein) and DSP216 (HLA-G x CD47 targeting fusion protein) which are in preclinical development.